You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Advanced therapeutic for Parkinson's Disease
SBC: Inhibikase Therapeutics, Inc. Topic: 999Parkinsonandapos;s Disease (PD) is a progressive neurodegenerative disorder that affects ≈1 million patient in the U.S. annually and 7 to 10 million people worldwide. PD is characterized by disorders of movement, which are caused by the progressive loss of dopamine neurons in the substantia nigra pars compacta (SNpc), and autonomic dysfunction, anxiety, depression, sleep disorders and cognitive ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.
SBC: Vova Ida, LLC Topic: 999SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Next Generation Tools for Onsite Monitoring and Treatment of Drug of Abuse-Dependent Persons
SBC: SensoDX II, LLC Topic: NIDAAbstract Opioid abuse disorder (OAD) affects 2.1 million of Americans annually resulting in overdoses numbering in the tens of thousands and skyrocketing rates of mortality. In addition to its enormous social impact, OAD carries a multi-billion-dollar price tag that includes $78.5 billion, specifically for health care and other costs related to prescription opioid abuse and misuse. Although effect ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Resveratrol as a Corneal Pain Therapeutic
SBC: TED'S BRAIN SCIENCE INCORPORATED Topic: NMore thanindividuals undergo laser vision correction surgery each year in the United Statesincluding laser assisted in situ keratomileusisLASIKand photorefractive keratectomyPRKThese procedures damage the nerves in the corneal epithelium causing intense acute pain that most patients rate as greater thanon ascalemany report the pain to beunbearableeven after analgesic treatmentWhile virtually all p ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Human Neural Cell Exosomes as a Therapeutic Treatment for Stroke
SBC: ARUNA BIO, INC. Topic: NINDSProject Summary Cytoprotective and restorative treatments for acute ischemic stroke (AIS) is a major unmet medical need. The current standard of care for stroke patients is centered on recanalization efforts to restore cerebral perfusion through the administration of tissue plasminogen activator (tPA) or mechanical thrombectomy. However, despite a recent extension of recanalization treatment windo ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Addressing Opioid Use Disorder with an External Multimodal Neuromodulation Device: Development and Clinical Evaluation of DuoTherm for Opioid-Sparing in Acute and Chronic Low Back Pain.
SBC: MMJ Labs, LLC Topic: NIDAProject Summary The goal of this project is to develop a multimodal neuromodulatory opioid sparing device for low back paindemonstrate effective pain reliefthen evaluate opioid reduction for patients with acute or chronic back pain presenting for treatmentPain and opioid use disorderOUDare intricately relateddependence begins for up towith medications prescribed for paineither directly or through ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Transcutaneous auricular neurostimulation for neonatal abstinence syndrome
SBC: SPARK BIOMEDICAL INC. Topic: R43Neonatal abstinence syndromeNASis a condition in which infants undergo withdrawal after exposure to prescription or non prescription opioids such as methadone or heroin in uteroNAS babies exhibit hyperirritability of the central nervous system and respiratorygastrointestinaland autonomic symptomsThese symptoms usually appear withintohours after birthAs ofan infant with NAS was born everyminutes in ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Novel Strategies for Development of a Multiplexed Test with Expanded Content for Spinal Muscular Atrophy
SBC: ASURAGEN, INC. Topic: 102SummaryThe overall goal of this project is to develop a cost effective multiplexed diagnostic test for spinal muscular atrophySMAto rapidly and accurately analyze multiple classes of disease causingdisease modifying DNA variantsand carrier status markersUltimatelythe proposed test will have a far reaching impact by expanding the identification and stratification of patients who may benefit from ne ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a rapid diagnostic assay for Myasthenia Gravis
SBC: ATTOGENE CORPORATION Topic: 101Project Summary AbstractThe physiological effect of autoantibody binding to the motor endplate junction nicotinic acetylcholine receptorsAchRcauses numerous symptoms associated with Myasthenia GravisMGand is characterized by drooping of one or both eyesblurred or double visionchange in facial expressiondifficulty swallowingshortness of breathimpaired speech and weakness of muscle functionIn some c ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
HLS- SBIR Phase I: Targeted platelet-capsule hybrids for on demand treatment in hemophilia
SBC: Split Rock Therapeutics, LLC Topic: NHLBIPROJECT SUMMARY ABSTRACTHemophilia A affectspeople in the USclassifying it as an Orphan Diseaseand is characterized by the inability to produce functional factor VIIIfVIIIa plasma protein necessary for blood clot formationof those with severe hemophilia A have inhibitory antibodies to the commonly used drugwhich is intravenous infusion of plasma derived or recombinant fVIIIThese patients represent ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health